Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

156332

	registered interest
	date	18/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs: Licensing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many full-time equivalent officials in his Department work on the availability of off-patent drugs to be used in new indications.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Michael Connarty
	uin	215052
	answer	answer is ministerial correction date of answer 25/11/2014 answer text <p>These issues are relevant to the responsibilities of a number of officials in the Department and in the Medicines and Healthcare products Regulatory Agency. The amount of official time spent on such issues is not fixed and will vary.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/11/2014 17:40:27 answering member 4020 label Biography information for George Freeman
	tabling member	602 label Biography information for Michael Connarty

746856

	registered interest
	date	29/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will bring forward proposals to increase funding for brain tumour research over the current Parliament; and if he will make a statement.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	2093
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The Department Task and Finish Working Group on Brain Tumour Research is bringing together clinicians, charities, patients, and officials to discuss how, working together with research funding partners, we can address the need to increase the level and impact of research into brain tumours. The Working Group is chaired by Professor Chris Whitty, the Department's Chief Scientific Adviser. The Working Group met for the third time on 17 May, and plans to report to the Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) by autumn 2017.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 04/07/2017 14:10:18 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4488 label Biography information for Martyn Day

443898

	registered interest
	date	11/01/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Fast Food: Packaging
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to establish an inquiry into the use of perfluorochemicals in fast-food packaging.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	21723
	answer	answer is ministerial correction date of answer 18/01/2016 answer text <p>European Union Legislation already requires that food contact materials must not transfer harmful chemicals into food. Recent reports in the media have referred to changes being introduced in the United States to ban the use of some perfluorochemicals in food packaging. The Food Standards Agency has confirmed that perfluorochemicals are not used in paper and cardboard fast food packaging in the United Kingdom and will continue to work with the industry to ensure they meet their responsibilities under the legislation.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 18/01/2016 16:23:31 answering member 3918 label Biography information for Jane Ellison
	tabling member	4488 label Biography information for Martyn Day

731287

	registered interest
	date	21/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nurses: Migrant Workers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of the UK leaving the EU on the number of nurses from the EU working in the NHS.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	61
	answer	answer is ministerial correction date of answer 27/06/2017 answer text <p>We are monitoring the impact on the National Health Service.</p><p> </p><p>The latest NHS Digital data available on nationality shows the number of nurses with European Union (excluding United Kingdom) nationalities (EU27) has increased by over 400 between June 2016 and March 2017. This number as a percentage of all nurses has also increased slightly, from 6.9% to 7.0%.</p><p> </p><p>NHS Digital publishes data on the nationality of staff working in the National Health Service in England. Nationality is self-reported within the NHS human resources and payroll system, the electronic staff record.</p><p> </p><p>The Secretary of State has repeatedly said that overseas workers form a crucial part of our NHS and we value their contribution immensely.</p><p> </p><p>We understand the need to give valued NHS staff from the EU certainty, which is why securing an agreement that will guarantee the status of EU nationals here and UK nationals in the EU is one of our top priorities in Brexit negotiations.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 27/06/2017 15:30:12 answering member 1542 label Biography information for Philip Dunne
	tabling member	4488 label Biography information for Martyn Day

732999

	registered interest
	date	27/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect on obtaining authorisations for new drugs of the UK withdrawing from the European Medicines Agency.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	1340
	answer	answer is ministerial correction date of answer 05/07/2017 answer text <p>The extent to which European Medicines Agency procedures will apply in the United Kingdom after we have exited the European Union will be subject to negotiations. Whatever the outcome of negotiations, the Government will ensure that we have a regulatory system that protects the best interests of patients – without regulatory delay in the approval of new medicines - and encourages innovation.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/07/2017 08:23:01 answering member 4067 label Biography information for Steve Brine
	tabling member	4488 label Biography information for Martyn Day

694234

	registered interest
	date	24/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his Department's policies of recommendations made by the Brain Tumour Charity in its Patient Guide to Brain Tumour Treatment and Services, published in November 2016.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	65516
	answer	answer is ministerial correction date of answer 06/03/2017 answer text <p>The recommendations made by The Brain Tumour Charity in its report and guidance align with the recommendations in the independent Cancer Taskforce’s 2015 report, <em>Achieving World-Class Cancer Outcomes: A strategy for England 2015-2020<sup>1</sup></em>, which represented the consensus views of the whole cancer community.</p><p> </p><p>Improving early diagnosis of cancer is a priority for this Government. We have committed to delivering the independent Taskforce’s recommendations on early diagnosis, including the introduction of a 28 day waiting times standard. NHS England’s Accelerate, Co-ordinate, Evaluate programme is testing innovative ways of diagnosing cancer earlier. The second wave of the programme is piloting multi-disciplinary diagnostic centres for patients with vague or non-specific symptoms. The pilots are taking place in London, Greater Manchester, Leeds, Bristol, Oxfordshire and Airedale, Wharfedale and Craven (Yorkshire).</p><p> </p><p>Additionally, patient experience was one of the six strategic priorities identified by the independent Cancer Taskforce, and ‘overall patient experience’ is one of the four key metrics included in the Clinical Commissioning Group Improvement and Assessment Framework published for the first time in 2016.</p><p> </p><p>A new Department of Health Task and Finish Working Group on Brain Tumour Research is bringing together clinicians, charities, patients, and officials to discuss how, working together with research funding partners, we can address the need to increase the level and impact of research into brain tumours. The Working Group is chaired by Professor Chris Whitty, the Department's Chief Scientific Adviser. The Working Group met for the second time on 30 January, and plans to report to the Parliamentary Under Secretary of State for Public Health and Innovation by summer 2017.</p><p> </p><p>The Department’s National Institute for Health Research (NIHR) supports brain tumour clinical trials via its Biomedical Research Centres, Clinical Research Facilities, and its Clinical Research Network (CRN). The CRN comprises 15 Local CRNs (LCRNs). In a new initiative from April 2015, each of these LCRNs has designated a senior clinician as the Subspecialty Lead for Brain Tumours. These local leaders are liaising with the National Cancer Research Institute’s Clinical Studies Groups to help plan the development and delivery of the national portfolio of brain tumour research, identifying new research opportunities and areas of clinical need. In the financial year 2015/16 the NIHR CRN supported recruitment of 1,061 patients to 37 brain cancer studies.</p><p> </p><p>To support people after treatment ends, in December 2016, NHS England announced a fund of over £200 million available to Cancer Alliances over the next two years, specifically to support those areas of the Cancer Taskforce strategy that it estimated would need significant investment. This includes implementation of the Recovery Package so that patients have personalised care and support from the point they are diagnosed to improve their quality of life.</p><p> </p><p>The report also included recommendations on palliative care. The Government’s ambition is for everyone approaching the end of life to receive high quality care that reflects their individual needs, choices and preferences. On 5 July 2016, we set out plans to improve end of life care in England. Our proposals are based on a commitment to high quality, personalised end of life care that we are making to all people at, or approaching the end of life.</p><p> </p><p>Note:</p><p> </p><p><sup>1</sup> <a href="http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf" target="_blank">http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf</a></p><p> </p><p> </p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 65517 question first answered 06/03/2017 15:21:01 answering member 4080 label Biography information for David Mowat
	tabling member	4488 label Biography information for Martyn Day

694235

	registered interest
	date	24/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his Department's policies of recommendations made by the Brain Tumour Charity in its report, Finding Myself: The Reality of Brain Tumour Treatment and Care, published in February 2016.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	65517
	answer	answer is ministerial correction date of answer 06/03/2017 answer text <p>The recommendations made by The Brain Tumour Charity in its report and guidance align with the recommendations in the independent Cancer Taskforce’s 2015 report, <em>Achieving World-Class Cancer Outcomes: A strategy for England 2015-2020<sup>1</sup></em>, which represented the consensus views of the whole cancer community.</p><p> </p><p>Improving early diagnosis of cancer is a priority for this Government. We have committed to delivering the independent Taskforce’s recommendations on early diagnosis, including the introduction of a 28 day waiting times standard. NHS England’s Accelerate, Co-ordinate, Evaluate programme is testing innovative ways of diagnosing cancer earlier. The second wave of the programme is piloting multi-disciplinary diagnostic centres for patients with vague or non-specific symptoms. The pilots are taking place in London, Greater Manchester, Leeds, Bristol, Oxfordshire and Airedale, Wharfedale and Craven (Yorkshire).</p><p> </p><p>Additionally, patient experience was one of the six strategic priorities identified by the independent Cancer Taskforce, and ‘overall patient experience’ is one of the four key metrics included in the Clinical Commissioning Group Improvement and Assessment Framework published for the first time in 2016.</p><p> </p><p>A new Department of Health Task and Finish Working Group on Brain Tumour Research is bringing together clinicians, charities, patients, and officials to discuss how, working together with research funding partners, we can address the need to increase the level and impact of research into brain tumours. The Working Group is chaired by Professor Chris Whitty, the Department's Chief Scientific Adviser. The Working Group met for the second time on 30 January, and plans to report to the Parliamentary Under Secretary of State for Public Health and Innovation by summer 2017.</p><p> </p><p>The Department’s National Institute for Health Research (NIHR) supports brain tumour clinical trials via its Biomedical Research Centres, Clinical Research Facilities, and its Clinical Research Network (CRN). The CRN comprises 15 Local CRNs (LCRNs). In a new initiative from April 2015, each of these LCRNs has designated a senior clinician as the Subspecialty Lead for Brain Tumours. These local leaders are liaising with the National Cancer Research Institute’s Clinical Studies Groups to help plan the development and delivery of the national portfolio of brain tumour research, identifying new research opportunities and areas of clinical need. In the financial year 2015/16 the NIHR CRN supported recruitment of 1,061 patients to 37 brain cancer studies.</p><p> </p><p>To support people after treatment ends, in December 2016, NHS England announced a fund of over £200 million available to Cancer Alliances over the next two years, specifically to support those areas of the Cancer Taskforce strategy that it estimated would need significant investment. This includes implementation of the Recovery Package so that patients have personalised care and support from the point they are diagnosed to improve their quality of life.</p><p> </p><p>The report also included recommendations on palliative care. The Government’s ambition is for everyone approaching the end of life to receive high quality care that reflects their individual needs, choices and preferences. On 5 July 2016, we set out plans to improve end of life care in England. Our proposals are based on a commitment to high quality, personalised end of life care that we are making to all people at, or approaching the end of life.</p><p> </p><p>Note:</p><p> </p><p><sup>1</sup> <a href="http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf" target="_blank">http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf</a></p><p> </p><p> </p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 65516 question first answered 06/03/2017 15:21:02 answering member 4080 label Biography information for David Mowat
	tabling member	4488 label Biography information for Martyn Day

444233

	registered interest
	date	12/01/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmacy: Negligence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the potential role of technology in reducing aseptic pharmaceutical medication error.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	22182
	answer	answer is ministerial correction date of answer 20/01/2016 answer text <p>Where appropriate, automation has a role to play in ensuring consistent output from aseptic compounding and increased production capacity. It may also provide additional protection against microbiological contamination by use of ‘closed systems’ of manufacture.</p><br /><p>Licensed specials manufacturers may consider automation as an appropriate solution for their product range and capacity. In these cases, Medicines and Healthcare products Regulatory Agency inspections assess whether the process design, validation, personnel, training and procedures relating to the automated system comply with the requirements of Good Manufacturing Practice.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/01/2016 12:34:51 answering member 4020 label Biography information for George Freeman
	tabling member	4488 label Biography information for Martyn Day

449422

	registered interest
	date	01/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Zika Virus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the risk to the UK and Europe of the spread of the Zika virus.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	25164
	answer	answer is ministerial correction date of answer 09/02/2016 answer text <p>Public Health England (PHE) continue to monitor the situation closely and have provided revised travel advice and updated guidance to healthcare professionals on the management of patients returning from affected countries who present with symptoms. There is no evidence to suggest that the mosquitos that are known to carry Zika are established in the United Kingdom or could survive in our climate and therefore the risk to the UK population from Zika is very low. PHE is in regular contact with specialists in other European countries, as well as internationally, to make sure all necessary steps are being taken to protect the UK travelling public.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 09/02/2016 16:15:22 answering member 3918 label Biography information for Jane Ellison
	tabling member	4488 label Biography information for Martyn Day

732562

	registered interest
	date	26/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neuromuscular Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what proposals he has made to ensure that patients do not experience delays in accessing emerging treatments for muscle-wasting conditions after the UK leaves the EU.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	1192
	answer	answer is ministerial correction date of answer 29/06/2017 answer text <p>The Government wants patients to access cost-effective innovative medicines and technologies, which may include emerging treatments for muscle-wasting conditions, at a price that the National Health Service can afford. That is why we commissioned the Accelerated Access Review, which reported in October last year. We are considering the review’s recommendations and will respond in due course.</p><p> </p><p>As part of the exit negotiations the Government will discuss with the European Union and Member States how best to continue cooperation on medicine research and development and regulation in the best interests of both the United Kingdom and the EU. It would not be appropriate to pre-judge the outcome of the negotiations, but we are clear that whatever happens NHS patients should have access to cost-effective life-changing treatments as soon as possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/06/2017 11:03:21 answering member 4067 label Biography information for Steve Brine
	tabling member	4488 label Biography information for Martyn Day